Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Receivables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Receivables over the past 15 years, most recently at $20.5 million for Q2 2025.

  • For Q2 2025, Receivables rose 0.85% year-over-year to $20.5 million; the TTM value through May 2025 reached $20.5 million, up 0.85%, while the annual FY2025 figure was $20.5 million, 42.9% down from the prior year.
  • Receivables for Q2 2025 was $20.5 million at Lifecore Biomedical, Inc. \De\, down from $22.3 million in the prior quarter.
  • Over five years, Receivables peaked at $53.6 million in Q1 2022 and troughed at $13.7 million in Q4 2023.
  • A 5-year average of $31.2 million and a median of $34.2 million in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: crashed 66.77% in 2023 and later surged 163.34% in 2024.
  • Year by year, Receivables stood at $40.1 million in 2021, then fell by 10.57% to $35.9 million in 2022, then crashed by 61.87% to $13.7 million in 2023, then skyrocketed by 163.34% to $36.0 million in 2024, then crashed by 43.01% to $20.5 million in 2025.
  • Business Quant data shows Receivables for LFCR at $20.5 million in Q2 2025, $22.3 million in Q1 2025, and $36.0 million in Q4 2024.